All In Biotech

Drug Trial Radar · NCT04169997

A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer

A Phase III Study to Evaluate the Efficacy and Safety of IMP4297 Following 1st Line Chemotherapy in the Monotherapy Maintenance Treatment of Subjects With Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 404 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

404

Actual

Start

Dec 24, 2019

Primary completion

Mar 16, 2023

Study completion Jun 30, 2026

Sponsor

Lead sponsor
Impact Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 20, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

IMP4297 is a PARP inhibitor. This is a 2:1 randomized, double-blind, placebo-controlled study conducted in patients with advanced (FIGO Stage III or IV) ovarian cancer to evaluate Efficacy and Safety of IMP4297 for Maintenance Treatment

Conditions

  • Ovarian Cancer

Interventions

  • IMP4927Drug

    IMP4297 tablet.The starting dose from 100mg QD

  • PlacebosDrug

    Placebos tablet.The starting dose from 100mg QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: Approximately 42 months since the first subject enrolled

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guanzhou, Guangdong, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.